Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
75
ABOS Quote, Financials, Valuation and Earnings
Last price:
$2.57
Seasonality move
:
-13.66%
Day range:
$2.56 - $2.75
52-week range:
$0.86 - $3.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.67x
Volume:
221.5K
Avg. volume:
1M
1-year change:
86.23%
Market cap:
$155.7M
Revenue:
--
EPS (TTM):
-$2.21
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ABOS
Acumen Pharmaceuticals, Inc.
|
-- | -$0.56 | -- | -10.03% | $7.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835M | $0.56 | 11.9% | 36.21% | $88.87 |
|
IMNN
Imunon, Inc.
|
-- | -$1.82 | -- | -269.06% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ABOS
Acumen Pharmaceuticals, Inc.
|
$2.57 | $7.00 | $155.7M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.99 | $31.21 | $4.1B | 15.44x | $0.00 | 0% | 3.86x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$336.19 | $457.00 | $44.6B | 148.95x | $0.00 | 0% | 12.08x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$64.08 | $88.87 | $12.3B | 24.01x | $0.00 | 0% | 4.06x |
|
IMNN
Imunon, Inc.
|
$3.22 | $21.50 | $6.8M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$5.53 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ABOS
Acumen Pharmaceuticals, Inc.
|
24.87% | 2.253 | 29.77% | 5.77x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.236 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ABOS
Acumen Pharmaceuticals, Inc.
|
-$47K | -$26.5M | -72.85% | -87.18% | -- | -$30.5M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Acumen Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ABOS or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Acumen Pharmaceuticals, Inc.'s net margin of 25.76%. Acumen Pharmaceuticals, Inc.'s return on equity of -87.18% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital ABOSAcumen Pharmaceuticals, Inc.-- -$0.44 $124M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About ABOS or ACAD?
Acumen Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 172.37%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 30.1%. Given that Acumen Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Acumen Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABOSAcumen Pharmaceuticals, Inc.6 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is ABOS or ACAD More Risky?
Acumen Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock ABOS or ACAD?
Acumen Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acumen Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABOS or ACAD?
Acumen Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Acumen Pharmaceuticals, Inc.'s net income of -$26.5M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Acumen Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acumen Pharmaceuticals, Inc. is -- versus 3.86x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABOSAcumen Pharmaceuticals, Inc.-- -- -- -$26.5M ACADACADIA Pharmaceuticals, Inc.3.86x 15.44x $278.6M $71.8M
-
Which has Higher Returns ABOS or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Acumen Pharmaceuticals, Inc.'s net margin of 16.99%. Acumen Pharmaceuticals, Inc.'s return on equity of -87.18% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital ABOSAcumen Pharmaceuticals, Inc.-- -$0.44 $124M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About ABOS or ALNY?
Acumen Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 172.37%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 35.94%. Given that Acumen Pharmaceuticals, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Acumen Pharmaceuticals, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABOSAcumen Pharmaceuticals, Inc.6 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is ABOS or ALNY More Risky?
Acumen Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock ABOS or ALNY?
Acumen Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acumen Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABOS or ALNY?
Acumen Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Acumen Pharmaceuticals, Inc.'s net income of -$26.5M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Acumen Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 148.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acumen Pharmaceuticals, Inc. is -- versus 12.08x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABOSAcumen Pharmaceuticals, Inc.-- -- -- -$26.5M ALNYAlnylam Pharmaceuticals, Inc.12.08x 148.95x $1.1B $186.4M
-
Which has Higher Returns ABOS or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Acumen Pharmaceuticals, Inc.'s net margin of -3.91%. Acumen Pharmaceuticals, Inc.'s return on equity of -87.18% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital ABOSAcumen Pharmaceuticals, Inc.-- -$0.44 $124M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About ABOS or BMRN?
Acumen Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 172.37%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 38.69%. Given that Acumen Pharmaceuticals, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Acumen Pharmaceuticals, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABOSAcumen Pharmaceuticals, Inc.6 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is ABOS or BMRN More Risky?
Acumen Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock ABOS or BMRN?
Acumen Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acumen Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABOS or BMRN?
Acumen Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Acumen Pharmaceuticals, Inc.'s net income of -$26.5M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Acumen Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 24.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acumen Pharmaceuticals, Inc. is -- versus 4.06x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABOSAcumen Pharmaceuticals, Inc.-- -- -- -$26.5M BMRNBioMarin Pharmaceutical, Inc.4.06x 24.01x $786.8M -$30.7M
-
Which has Higher Returns ABOS or IMNN?
Imunon, Inc. has a net margin of -- compared to Acumen Pharmaceuticals, Inc.'s net margin of --. Acumen Pharmaceuticals, Inc.'s return on equity of -87.18% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital ABOSAcumen Pharmaceuticals, Inc.-- -$0.44 $124M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About ABOS or IMNN?
Acumen Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 172.37%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 567.7%. Given that Imunon, Inc. has higher upside potential than Acumen Pharmaceuticals, Inc., analysts believe Imunon, Inc. is more attractive than Acumen Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABOSAcumen Pharmaceuticals, Inc.6 0 0 IMNNImunon, Inc.3 1 0 -
Is ABOS or IMNN More Risky?
Acumen Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.135, suggesting its more volatile than the S&P 500 by 113.504%.
-
Which is a Better Dividend Stock ABOS or IMNN?
Acumen Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acumen Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABOS or IMNN?
Acumen Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. Acumen Pharmaceuticals, Inc.'s net income of -$26.5M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, Acumen Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acumen Pharmaceuticals, Inc. is -- versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABOSAcumen Pharmaceuticals, Inc.-- -- -- -$26.5M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns ABOS or SVRA?
Savara, Inc. has a net margin of -- compared to Acumen Pharmaceuticals, Inc.'s net margin of --. Acumen Pharmaceuticals, Inc.'s return on equity of -87.18% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital ABOSAcumen Pharmaceuticals, Inc.-- -$0.44 $124M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About ABOS or SVRA?
Acumen Pharmaceuticals, Inc. has a consensus price target of $7.00, signalling upside risk potential of 172.37%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 95.52%. Given that Acumen Pharmaceuticals, Inc. has higher upside potential than Savara, Inc., analysts believe Acumen Pharmaceuticals, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABOSAcumen Pharmaceuticals, Inc.6 0 0 SVRASavara, Inc.6 0 0 -
Is ABOS or SVRA More Risky?
Acumen Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock ABOS or SVRA?
Acumen Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acumen Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABOS or SVRA?
Acumen Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Acumen Pharmaceuticals, Inc.'s net income of -$26.5M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Acumen Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acumen Pharmaceuticals, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABOSAcumen Pharmaceuticals, Inc.-- -- -- -$26.5M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
